News & Events
- Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
- Seres Therapeutics to Present at JMP Securities Life Sciences Conference
- Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
- Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
- Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
- Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
- Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
- Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
- Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
- Genetic Analysis Joins Microbiome Therapeutics Innovation Group
- Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
- Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
- Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit